信实科技/人类Trem-1 Fc/10µg/S01-049S
市场价：
¥1500.00
美元价：
900.00
产品分类：
细胞代谢
公司分类：
cellular_metabolism
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Cat-Nr. | S01-049S |
| Size | 10 µg |
| Price | 75 € |
| Source | CHO cells |
| Label | Fc-Tag |
| Formulation | lyophilized |
| Purity Confirmation | > 95% by SDS-PAGE & HPLC analyses |
| Length [aa] | 413 |
| Molecular Weight | 92.6 kDa |
| Endotoxin Levels | < 0.1 ng/µg of protein (<1EU/µg) |
| Biological Activity | Not available. |
| Species Reactivity | Human |
| Synonyms | Triggering receptor expressed on monocytes 1, CD354 |
| Description | Triggering receptor expressed on myeloid cells-1 (TREM-1) is a type 1 transmembrane glycoprotein belonging to the immunoglobulin superfamily of cell surface receptors that is constitutively expressed on the surface of monocytes, neutrophils and macrophages. The first identified member of the TREM family of receptors, TREM-1 is a proponent of amplified inflammatory responses triggered by bacterial and fungal infection, and functions in association with the signal transduction adaptor molecule DAP12. TREM-1 activation induces the sustained secretion of proinflammatory chemokines (IL-8 and MCP-1) and cytokines (TNF-α, IL-1β, and IL-6), the respiratory burst and degranulation of neutrophils, the upregulation of adhesion molecules involved in leukocyte extravasation, and tissue degradation. Involvement and increased expression of TREM-1, or soluble TREM-1, in infectious, as well as some non-infectious, inflammatory conditions may highlight the protein’s potential as a possible diagnostic marker in cases of severe inflammation, such as myocardial dysfunction related to severe sepsis and spontaneous preterm labor. TREM-1 involvement in inflammatory response has also been noted as a predictor of both progression and aggression in certain cancers. Recombinant Human TREM-1 Fc is a glycosylated, disulfide-linked homodimer of 826 amino acid residues whose monomer consists of the 180-amino-acid length extracellular portion of TREM-1 fused to the 231-amino-acid length Fc portion of human IgG1 by two glycines. The calculated molecular weight of Recombinant Human TREM-1 Fc dimer is 92.6 kDa; however, due to glycosylation, the monomer and dimer migrate at apparent molecular weights of approximately 60-65 kDa and 110-116 kDa by SDS-PAGE analysis under reducing conditions. |
| Protein Sequence | ATKLTEEKYE LKEGQTLDVK CDYTLEKFAS SQKAWQIIRD GEMPKTLACT ERPSKNSHPV QVGRIILEDY HDHGLLRVRM VNLQVEDSGL YQCVIYQPPK EPHMLFDRIR LVVTKGFSGT PGSNENSTQN VYKIPPTTTK ALCPLYTSPR TVTQAPPKST ADVSTPDSEI NLTNVTDIIR GGPKSCDKTH TCPPCPAPEL LGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS RDELTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK |
| Uniprot ID | Q9NP99 |
| Protein RefSeq | NP_061113.1 |
| mRNA RefSeq | NM_018643.4 |
品牌介绍
Receptor Ligand Technologies GmbH 公司（RELIA Tech ）位于德国不伦瑞克，是一家后基因组生物技术公司，该公司运用独特的技术专注于受体和配体的发现与研究，从而使商业化，产品广泛使用于科学研究，实验诊断和临床应用。瑞莱技术的灵活性和竞争力必将使其在这个快速整合的功能基因组学和蛋白组学的新时代发展壮大.RELIA公司提供的细胞因子，生长因子，重组蛋白产品一致内毒素检测项目，且内毒素水平非常低。 受体配体技术有限公司（RELIATech）是一家后基因组生物技术公司，致力于在配体与受体相互作用领域的新技术和新产品的发现和商业化，用于研究，诊断和临床领域。该公司位于德国不伦瑞克，由以下公司成立于2000年10月： 阿夫纳·亚永教授以色列魏兹曼科学研究所（WIS） 赫伯特·韦奇博士德国生物技术德国研究中心（GBF） Bernhard Barleon博士德国肿瘤生物学诊所（KTB） 创始人是从事细胞生长因子相互作用，酪氨酸激酶及其信号传导途径（涉及组织重塑，体内平衡和疾病）领域的细胞和分子生物学家，工作时间超过10年。特别是Herbert A. Weich博士和Bernhard Barleon博士从事血管生成，肿瘤血管生成和实体瘤进展领域的基础研究。 诸如“生长因子和细胞因子”之类的信号蛋白，连同其跨膜/“可溶性受体”和相关的激酶，在生理和病理生理条件下都作为关键的调节分子参与了所有高级生物的发育和功能。这些多肽调节细胞分化，组织重塑和体内平衡，并在各种疾病状态下被失调。由人类基因组计划编码新信号蛋白的新生长调节基因的发现，以及对它们功能的阐明，无疑将是未来十年的主要挑战之一。 RELIATech的使命是开发和商品化在“受体和配体相互作用”领域中有用的新产品，用于基础研究，药物开发和临床社区。RELIATech的灵活性和能力必将使其在功能基因组学和蛋白质组学的新时代迅速整合和扩展。
联络我们
